Ocuphire Pharma, Inc.·4

Feb 1, 4:23 PM ET

Zaremba Rabourn Amy 4

4 · Ocuphire Pharma, Inc. · Filed Feb 1, 2022

Insider Transaction Report

Form 4
Period: 2022-01-28
Zaremba Rabourn Amy
Head of Fin. Quality Assurance
Transactions
  • Award

    Employee Stock Option (right to buy)

    2022-01-28+50,00050,000 total
    Exercise: $2.90Exp: 2032-01-27Common Stock (50,000 underlying)
Footnotes (1)
  • [F1]The option will vest with respect to 12,500 shares on January 28, 2023, and then with respect to 1,041 shares on the last day of each month from February 2023 through December 2025 and with respect to 1,065 shares at the end of January 2026.

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4